Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology

    Research output: Contribution to journalReview article

    19 Citations (Scopus)

    Abstract

    Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal agents such as nitrates, calcium channel antagonists, classic beta-adrenoceptor blockers and nicorandil have been tried, with variable success. However, this might be related to a failure to target the underlying pathophysiology and, clearly, more effective therapies are needed. Supporting evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has come from the recent observation that basal superoxide production predicts future cardiovascular events in this patient group. This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.

    What's already known about this topic ?

    center dot Morbidity of patients with cardiac syndrome X is high.

    center dot The important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X.

    What does this article add ?

    center dot This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.

    Original languageEnglish
    Pages (from-to)49-58
    Number of pages10
    JournalCardiovascular Therapeutics
    Volume27
    Issue number1
    DOIs
    Publication statusPublished - 2009

    Keywords

    • Cardiac syndrome X
    • Chest pain
    • Endothelial dysfunction
    • Microvascular dysfunction
    • Normal coronary angiogram
    • NORMAL CORONARY ANGIOGRAMS
    • CARDIOVASCULAR MAGNETIC-RESONANCE
    • IMPROVES ENDOTHELIAL FUNCTION
    • CONVERTING ENZYME-INHIBITION
    • XANTHINE-OXIDASE INHIBITORS
    • EXERCISE-INDUCED ANGINA
    • ST SEGMENT DEPRESSION
    • LONG-TERM PROGNOSIS
    • C-REACTIVE PROTEIN
    • CHEST-PAIN

    Cite this

    @article{286d306ede264b46b8c40a81f337aaee,
    title = "Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology",
    abstract = "Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal agents such as nitrates, calcium channel antagonists, classic beta-adrenoceptor blockers and nicorandil have been tried, with variable success. However, this might be related to a failure to target the underlying pathophysiology and, clearly, more effective therapies are needed. Supporting evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has come from the recent observation that basal superoxide production predicts future cardiovascular events in this patient group. This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.What's already known about this topic ?center dot Morbidity of patients with cardiac syndrome X is high.center dot The important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X.What does this article add ?center dot This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.",
    keywords = "Cardiac syndrome X, Chest pain, Endothelial dysfunction, Microvascular dysfunction, Normal coronary angiogram, NORMAL CORONARY ANGIOGRAMS, CARDIOVASCULAR MAGNETIC-RESONANCE, IMPROVES ENDOTHELIAL FUNCTION, CONVERTING ENZYME-INHIBITION, XANTHINE-OXIDASE INHIBITORS, EXERCISE-INDUCED ANGINA, ST SEGMENT DEPRESSION, LONG-TERM PROGNOSIS, C-REACTIVE PROTEIN, CHEST-PAIN",
    author = "Lim, {Tiong K.} and Choy, {Anna Maria J.} and Faisel Khan and Belch, {Jill J. F.} and Struthers, {Allan D.} and Lang, {Chim C.}",
    year = "2009",
    doi = "10.1111/j.1755-5922.2008.00070.x",
    language = "English",
    volume = "27",
    pages = "49--58",
    journal = "Cardiovascular Therapeutics",
    issn = "1755-5914",
    publisher = "Wiley",
    number = "1",

    }

    TY - JOUR

    T1 - Therapeutic development in cardiac syndrome X

    T2 - a need to target the underlying pathophysiology

    AU - Lim, Tiong K.

    AU - Choy, Anna Maria J.

    AU - Khan, Faisel

    AU - Belch, Jill J. F.

    AU - Struthers, Allan D.

    AU - Lang, Chim C.

    PY - 2009

    Y1 - 2009

    N2 - Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal agents such as nitrates, calcium channel antagonists, classic beta-adrenoceptor blockers and nicorandil have been tried, with variable success. However, this might be related to a failure to target the underlying pathophysiology and, clearly, more effective therapies are needed. Supporting evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has come from the recent observation that basal superoxide production predicts future cardiovascular events in this patient group. This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.What's already known about this topic ?center dot Morbidity of patients with cardiac syndrome X is high.center dot The important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X.What does this article add ?center dot This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.

    AB - Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal agents such as nitrates, calcium channel antagonists, classic beta-adrenoceptor blockers and nicorandil have been tried, with variable success. However, this might be related to a failure to target the underlying pathophysiology and, clearly, more effective therapies are needed. Supporting evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has come from the recent observation that basal superoxide production predicts future cardiovascular events in this patient group. This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.What's already known about this topic ?center dot Morbidity of patients with cardiac syndrome X is high.center dot The important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X.What does this article add ?center dot This review will discuss the pathophysiology, current medical management and potential new pharmacological treatment for patients with cardiac syndrome X which target endothelial dysfunction and oxidative stress.

    KW - Cardiac syndrome X

    KW - Chest pain

    KW - Endothelial dysfunction

    KW - Microvascular dysfunction

    KW - Normal coronary angiogram

    KW - NORMAL CORONARY ANGIOGRAMS

    KW - CARDIOVASCULAR MAGNETIC-RESONANCE

    KW - IMPROVES ENDOTHELIAL FUNCTION

    KW - CONVERTING ENZYME-INHIBITION

    KW - XANTHINE-OXIDASE INHIBITORS

    KW - EXERCISE-INDUCED ANGINA

    KW - ST SEGMENT DEPRESSION

    KW - LONG-TERM PROGNOSIS

    KW - C-REACTIVE PROTEIN

    KW - CHEST-PAIN

    U2 - 10.1111/j.1755-5922.2008.00070.x

    DO - 10.1111/j.1755-5922.2008.00070.x

    M3 - Review article

    C2 - 19207480

    VL - 27

    SP - 49

    EP - 58

    JO - Cardiovascular Therapeutics

    JF - Cardiovascular Therapeutics

    SN - 1755-5914

    IS - 1

    ER -